A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. (Q33389419)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. |
scientific article |
Statements
1 reference
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. (English)
1 reference
Elena Lukina
1 reference
Nora Watman
1 reference
Elsa Avila Arreguin
1 reference
Maryam Banikazemi
1 reference
Marta Dragosky
1 reference
Marcelo Iastrebner
1 reference
Hanna Rosenbaum
1 reference
Mici Phillips
1 reference
Gregory M Pastores
1 reference
Daniel I Rosenthal
1 reference
Mathilde Kaper
1 reference
Tejdip Singh
1 reference
Ana Cristina Puga
1 reference
Peter L Bonate
1 reference
M Judith Peterschmitt
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference